Sinotau Pharmaceutical Group
Clinical trials sponsored by Sinotau Pharmaceutical Group, explained in plain language.
-
New scan could reveal which heart tissue can be saved
Diagnosis Recruiting nowThis study tests a new imaging method using a special dye (XTR003) combined with a standard sugar scan (FDG) to see which parts of the heart are still alive in people with heart failure from blocked arteries. About 40 to 60 adults with weak hearts will get this scan before and af…
Phase: PHASE2 • Sponsor: Sinotau Pharmaceutical Group • Aim: Diagnosis
Last updated May 20, 2026 11:55 UTC
-
New heart scan agent aims to spot dangerous blockages more accurately
Diagnosis Recruiting nowThis study tests whether a new injection called XTR004, used with a PET scan, can better detect blood-flow-blocking narrowings in the heart arteries of people with known or suspected stable coronary artery disease. About 395 adults aged 18 to 80 will receive the injection and und…
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Diagnosis
Last updated May 20, 2026 11:53 UTC
-
New imaging tracer for prostate cancer tested in healthy adults
Diagnosis Recruiting nowThis early-stage study tests a new imaging drug called Flotufolastat F-18 in 6 healthy Chinese adults. The drug is a radioactive tracer that helps spot prostate cancer cells on PET scans. The goal is to check its safety, how it spreads in the body, and the radiation dose received…
Phase: PHASE1 • Sponsor: Sinotau Pharmaceutical Group • Aim: Diagnosis
Last updated May 07, 2026 18:40 UTC